SCHEMBL2373608

SCHEMBL2373608

CN(C)c1ccc(C=Cc2ccc(OCCOCCOCCO)nc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 15/20 0.55
MAPT P10636 4/20 0.55
SNCA P37840 1/20 0.55
PTGS1 P23219 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
RAB9A P51151 1/20 0.42
HBB P68871 1/20 0.42
RELA Q04206 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
ALPG P10696 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40
GFER P55789 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373600 1.00 APP (0.55) APPMAPTSNCAPTGS1MEN1
SCHEMBL13863162 0.92 APP (0.62) APPMAPTSNCAPTGS1MEN1
SCHEMBL2374051 0.90 APP (0.69) APPMAPTSNCA
SCHEMBL2374061 0.90 APP (0.69) APPMAPTSNCA
SCHEMBL16786475 0.90 APP (0.69) APPMAPTSNCA
SCHEMBL13863163 0.88 APP (0.53) APPMAPTSNCAPTGS1MEN1
SCHEMBL13431716 0.88 APP (0.53) APPMAPTSNCAPTGS1MEN1
SCHEMBL2567719 0.87 APP (0.50) APPMAPTSNCAKMT2A
SCHEMBL2567715 0.87 APP (0.50) APPMAPTSNCAKMT2A
SCHEMBL32661351 0.87 APP (0.50) APPMAPTSNCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363392-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2017-05-03 EP disclosed
US-8840866-B2 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-23 US disclosed
US-8506929-B2 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-08-13 US disclosed
US-20130129624-A1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-05-23 US disclosed
EP-1999109-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2011-12-28 EP disclosed
EP-2363391-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
EP-2363392-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
US-7687052-B2 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-03-30 US disclosed
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-05-14 US disclosed
EP-1999109-A2 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES The Trustees Of The University Of Pennsylvania (US) 2008-12-10 EP disclosed
US-20080038195-A1 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-02-14 US disclosed
WO-2007126733-A2 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129624-A1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES APP, APBA1, PSEN1 APP 1/4885MAPT 7/4885SNCA 33/4885
US-20080038195-A1 radiolabeling; neurodegenerative diseases APP, PSEN1, HTT APP 1/4885MAPT 6/4885SNCA 10/4885
US-20090123369-A1 Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques APP, APBA1, PSEN1 APP 1/4885MAPT 7/4885SNCA 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.